FDA Stalls On Collegium's 'Abuse-Deterrent' Painkiller

Law360, New York (October 13, 2015, 6:24 PM EDT) -- The U.S. Food and Drug Administration didn't finish its review — which had been expected on Monday — of Collegium Pharmaceutical Inc.'s purported abuse-deterrent opioid painkiller that an FDA panel supported at a meeting last month, according to a statement on Monday by the drugmaker that didn't indicate a reason for the delay.

Collegium said in the statement that the agency had told it that it hadn't finished reviewing the drugmaker's new drug application for the opioid painkiller Xtampza, which would come in the form of an extended-release capsule mean to treat severe pain that needs "daily, around-the-clock, long-term opioid treatment,"...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!